Lorna Ewart is the Executive Vice President, Science for Emulate and is based in the United Kingdom (UK). Prior to joining Emulate, Ewart created Veroli Consulting Limited to work as an independent scientific consultant to academics, start-ups, biotech, and pharma. As a leader in Organs-on-Chips technology, Ewart positioned AstraZeneca at the leading edge of industrial adoption and as a valued partner across multiple external collaborations involving academic institutions, regulatory bodies, and technology developers.
She established the Centre of Excellence for Microphyisological Systems within AstraZeneca’s R&D Biopharmaceuticals Unit in Cambridge, UK. Before creating the Centre of Excellence, Ewart spent two years as the therapy area lead toxicologist for Respiratory and Inflammation in Gothenburg, Sweden. Following her Ph.D., she joined the Respiratory and Inflammation research area within AstraZeneca, optimizing efficacy in small molecules before moving into preclinical drug safety where she led a safety pharmacology team delivering GLP data across multiple therapeutic areas.
Ewart is a classically trained pharmacologist and obtained her honours degree at the University of Aberdeen and her Ph.D. at Sir John Vane’s William Harvey Research Institute in London. She is a fellow of the Royal Society of Biology and British Pharmacological Society.
